Gilead Sciences, Inc.
Every calculator, already run for GILD
Open the full toolkit →You have the numbers on GILD. Get the argument.
A written report on which of these readings actually decide the outcome for Gilead Sciences, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
27 analysts covering GILDAnalyst Price Target Disagreement for Gilead Sciences, Inc.
Wall Street's bull case implies +19% from the current price; the bear case implies -19%. A 38% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for GILD
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further,…
GILD — frequently asked
Is GILD a buy right now?
Wall Street's consensus rating on Gilead Sciences, Inc. is Buy across 27 analysts, with a mean price target of $158.65 (+5% vs. the current $150.93). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is GILD overvalued?
GILD trades at — trailing earnings, against a DCF fair value of $306 per share. The current price implies -3% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is GILD's next earnings date?
Gilead Sciences, Inc. is next scheduled to report earnings around Oct 29, 2026. A full GILD research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Gilead Sciences, Inc.?
Analysts covering Gilead Sciences, Inc. (GILD) range from a bear-case target of $123.00 to a bull-case high of $180.00, with a mean consensus target of $158.65 across 26 analysts. The spread of $57.00 (38% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Gilead Sciences, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Gilead Sciences, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full GILD research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Gilead Sciences, Inc., in minutes. 3 free reports included with every account — no credit card required.